Advertisement

Topics

Kite Pharma seeks European approval for Axicabtagene Ciloleucel

06:35 EDT 1 Aug 2017 | Pharmaceutical Business Review

Kite Pharma has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for axicabtagene ciloleucel as a treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) who are not eligible for autologous stem cell transplant.

Original Article: Kite Pharma seeks European approval for Axicabtagene Ciloleucel

NEXT ARTICLE

More From BioPortfolio on "Kite Pharma seeks European approval for Axicabtagene Ciloleucel"

Quick Search
Advertisement